EC Pulmonology and Respiratory Medicine

A comprehensive search was carried out in mainstream bibliographic databases or Medical Subject Headings, including ScienceDirect, PubMed, Scopus, and ISI Web of Science. The search was applied to the articles that were published between January 2020 and early 2023 With strict literature search and screening processes, it yielded 14 articles from 373 articles of initial literature database. Among 14 study results, there was acceptable for immunogenicity (both humoral and cellular immune responses (a key response for the development of a vaccination-induced immunogenicity and safety in 11 studies (78.57%), whereas acceptable potent immunogenicity was found in patients aged more than 40 years with chronic diseases, particularly, chronic respiratory diseases and coronary artery diseases, only potent T-cell response was identified in one study, and no significant difference in vaccine safety compared with healthy subjects and effective neutralizing antibodies (two doses completion) against SARS-CoV-2 (COVID-19) in patients older than 60 years with diabetes and/or hypertension were demonstrated after completion of COVID-19 vaccination. In conclusion, Immunogenicity (both humoral and cellular) and safety in aged people and individuals living with various chronic diseases (both infectious and non-infectious) is highlighted in this study and can decrease COVID-19 vaccination hesitancy in these persons.

Keywords: Adverse Reactions; COVID-19; Immunogenicity; Neutralizing Antibody; Safety; Vaccine; Titer

1. Keech C., et al. “Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine”. The New England Journal of Medicine24 (2020): 2320-2332.
2. Hall VG., et al. “Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients”. The New England Journal of Medicine 385 (2021): 1244-1246.
3. Kamar N., et al. “Three doses of an mRNA COVID-19 vaccine in solid-organ transplant recipients”. The New England Journal of Medicine 385 (2021): 661-662.
4. Benotmane I., et al. “Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in kidney-transplant recipients with minimal serologic response to 2 doses”. The Journal of the American Medical Association 326 (2021): 1063-1065.
5. Saiag E., et al. “The effect of a third-dose BNT162b2 vaccine on anti-SARS-CoV-2 antibody levels in immunosuppressed patients”. Clinical Microbiology and Infection 28 (2022): 735.e5-735.e8.
6. Aikawa NE., et al. “Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases”. Annals of the Rheumatic Diseases 81 (2022): 1036-1043.
7. Azzolini E., et al. “mRNA COVID-19 vaccine booster fosters B- and T-cell responses in immunocompromised patients”. Life Science Alliance 5 (2022): e202201381.
8. Tenforde MW., et al. “Effectiveness of a third dose of Pfizer-BioNTech and Moderna vaccines in preventing COVID-19 hospitalization among immunocompetent and immunocompromised adults-United States, August-December 2021”. Morbidity and Mortality Weekly Report 71 (2021): 118-124.
9. Yue L., et al. “Antibody response elicited by a third boost dose of inactivated SARS-CoV-2 vaccine can neutralize SARS-CoV-2 variants of concern”. Emerging Microbes and Infections 10 (2021): 2125-2127.
10. Schmiedeberg K., et al. “Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses”. The Lancet Rheumatology 4 (2022): e11-e13.
11. Karaba All., et al. “A third dose of SARS-CoV-2 vaccine increases neutralizing antibodies against variants of concern in solid-organ transplant recipients”. Med Rxiv (2021).
12. Bar-On YM., et al. “Protection of BNT162b2 vaccine booster against COVID-19 in Israel”. The New England Journal of Medicine 385 (2021): 1393-1400.
13. Bensouna I., et al. “SARS-CoV-2 antibody response after a third dose of the BNT162b2 vaccine in patients receiving maintenance hemodialysis or peritoneal dialysis”. American Journal of Kidney Diseases 79 (2022): 185-192.
14. Bertrand D., et al. “Antibody and T-cell response to a third dose of SARS-CoV-2 mRNA BNT162b2 vaccine in kidney-transplant recipients”. Kidney International 100 (2021): 1337-1340.
15. Le Bougeois A., et al. “Interest of a third dose of BNT162b2 anti-SARS-CoV-2 messenger-RNA vaccine after allotransplant”. British Journal of Haematology 196 (2022): e38-e40.
16. Marlet J., et al. “Antibody responses after a third dose of COVID-19 vaccine in kidney-transplant recipients and patients treated for chronic lymphocytic leukemia”. Vaccines 9 (2021): 1055.
17. Reindl-Schwaighofer R., et al. “Comparison of SARS-CoV-2 antibody response 4 weeks after homologous vs heterologous third vaccine dose in kidney-transplant recipients: a randomized clinical trial”. JAMA Internal Medicine 182 (2022): 165-171.
18. Mair MJ., et al. “Third dose of SARS-CoV-2 vaccination in hemato-oncological patients and healthcare workers: immune responses and adverse events-a retrospective cohort study”. The European Journal of Cancer 165 (2022): 184-194.
19. Kartnig F., et al. “Safty and immunogenicity of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases compared with healthy controls”. Annals of the Rheumatic Diseases 82 (2023): 292-300.
20. Kulkarni PS., et al. “Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomized controlled study”. The Lancet 10 (2023): 100139.
21. Kang L., et al. “Immunogenicity and safety of COVID-19 vaccines among people living with HIV: a systematic review and meta-analysis”. Vaccines 10 (2022): 1569.
22. Hibino M., et al. “Safety and immunogenicity of mRNA vaccines against severe acute respiratory syndrome coronavirus 2 in patients with lung cancer receiving immune checkpoint inhibitors: a multicenter observational study in Japan”. Journal of Thoracic Oncology8 (2022): 1002-1013.
23. Xia S., et al. “Safety and immunogenicity of an inactivated COVID-19 vaccine, WIBP-CorV, in healthy children: interim analysis of a randomized, double-blind, controlled, phase ½ trial”. Frontiers in Immunology 13 (2022): 898151.
24. Huang R., et al. “Safety and immunogenicity of inactivated SARS_CoV-2 vaccine (BBIBP-CorV) in hypertensive and/or diabetic people aged over 60 years: a prospective open-label study”. Diabetes Therapy 14 (2023): 139-151.
25. Yang B., et al. “Immunogenicity, efficacy, and safety of SARS-CoV-2 vaccine dose fractionation: a systematic review and meta-analysis”. BMC Medicine 20 (2022): 409.
26. Li C., et al. “Retrospective study of the CoronaVac SARS-CoV-2 vaccine in people with underlying medical conditions”. Communications Medicine (2022).
27. Song J-W., et al. “Safety and immunogenicity of COVID-19 vaccination in immunocompromised patients”. Chinese Medical Journal22 (2022): 2656-2666.
28. Zakarya K., et al. “Safety and immunogenicity of a QazCovid-in® inactivated whole-virion vaccine against COVID-19 in healthy adults: a single-centre, randomized, single-blind, placebo-controlled phase 1 and open-label phase 2 clinical trials with a 6 months follow-up in Kazakhstan”. EClinical Medicine 39 (2021): 101078.
29. French RWJr., et al. “Safety, immunogenicity, and efficacy of the BNT162b2 COVID-19 vaccine in adolescents”. The New England Journal of Medicine (2021).
30. Munro APS., et al. “Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCoV-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomized, controlled, phase 2 trial”. Lancet 398 (2021): 2258-2276.
31. Xia S., et al. “Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials”. The Journal of the American Medical Association10 (2020): 951-960.
32. Walsh EE., et al. “Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates”. The New England Journal of Medicine 383 (2020): 2439-2450.